Jefferies Group Analysts Boost Earnings Estimates for Enzymotec Ltd. (ENZY)
Enzymotec Ltd. (NASDAQ:ENZY) – Investment analysts at Jefferies Group upped their Q3 2017 EPS estimates for Enzymotec in a research note issued on Thursday. Jefferies Group analyst L. Alexander now forecasts that the biotechnology company will post earnings per share of $0.04 for the quarter, up from their prior forecast of $0.02.
Enzymotec (NASDAQ:ENZY) last announced its quarterly earnings results on Wednesday, August 16th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by $0.15. The company had revenue of $13 million during the quarter, compared to the consensus estimate of $12.78 million. Enzymotec had a negative return on equity of 3.88% and a negative net margin of 14.52%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the business posted $0.04 EPS.
Several other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Enzymotec from a “hold” rating to a “sell” rating in a research report on Monday, May 22nd. ValuEngine upgraded shares of Enzymotec from a “sell” rating to a “hold” rating in a research report on Saturday, August 12th. One equities research analyst has rated the stock with a sell rating and three have given a hold rating to the company. Enzymotec presently has a consensus rating of “Hold” and a consensus target price of $8.00.
Shares of Enzymotec (NASDAQ ENZY) opened at 10.55 on Monday. Enzymotec has a one year low of $5.20 and a one year high of $10.65. The company has a 50 day moving average price of $8.55 and a 200 day moving average price of $8.54. The company’s market cap is $242.11 million.
Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp boosted its stake in Enzymotec by 1.8% in the second quarter. State Street Corp now owns 20,952 shares of the biotechnology company’s stock worth $169,000 after buying an additional 380 shares in the last quarter. State of New Jersey Common Pension Fund D boosted its stake in Enzymotec by 12.5% in the first quarter. State of New Jersey Common Pension Fund D now owns 28,110 shares of the biotechnology company’s stock worth $247,000 after buying an additional 3,113 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Enzymotec by 3.2% in the first quarter. Acadian Asset Management LLC now owns 237,184 shares of the biotechnology company’s stock worth $2,088,000 after buying an additional 7,322 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in Enzymotec during the second quarter worth approximately $2,350,000. Institutional investors and hedge funds own 27.91% of the company’s stock.
Enzymotec Company Profile
Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings.
Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.